14052-82-5

Usage

InChI:InChI=1/C10H14Cl2N2O2/c1-3-15-8(16-4-2)5-7-9(11)13-6-14-10(7)12/h6,8H,3-5H2,1-2H3

Upstream product

• 40637-56-7 dimethyl allylmalonate 
• 122-51-0 orthoformic acid triethyl ester 
• 16019-33-3 2-(4,6-dichloropyrimidin-5-yl)acetaldehyde 
• 2049-80-1 (2-propenyl)propanedioic acid diethyl ester 
• 16019-30-0 5-(prop-2-en-1-yl)pyrimidine-4,6-diol 
• 64-17-5 ethanol 
• 16019-31-1 5-allyl-4,6-dichloropyrimidine 

Downstream Products

• 636583-26-1 (1R,2S,3R,5R)-3-((6-chloro-5-(2,2-diethoxyethyl)pyrimidin-4-yl)amino)-5-(hydroxymethyl)cyclopentane-1,2-diol 
• 1456534-46-5 4-chloro-5-(2,2-diethoxyethyl)-6-phenylpyrimidine 
• 1456534-31-8 1-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-(5-phenyl-3,4-dihydropyrimido[4,5-c]pyridazin-2(1H)-yl)ethane-1,2-dione 
• 1456534-47-6 2-(4-chloro-6-phenylpyrimidin-5-yl)acetaldehyde 
• 1456534-48-7 2-(4-chloro-6-phenylpyrimidin-5-yl)ethanol 
• 1456534-49-8 4-chloro-5-(2-chloroethyl)-6-phenylpyrimidine 
• 1456534-50-1 5-phenyl-1,2,3,4-tetrahydropyridazino[3,4-d]pyrimidine 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 1379540-62-1 [(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-6-yl]methanol 
• 905579-51-3 ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)-methyl sulfamate 
• 905580-90-7 (1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-(hydroxymethyl)-cyclopentanol 
• 1380350-96-8 ethyl 3-(3-((((3aR,4R,6R,6aS)-6-(4-((2,4-dimethoxybenzyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)(isobutyl)amino)cyclobutyl)propanoate 
• 1380350-89-9 3-(3-(cyclobutyl(((3aR,4R,6R,6aS)-6-(4-((2,4-dimethoxybenzyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)amino)cyclobutyl)propanoic acid 
• 1380350-88-8 ethyl 3-(3-(cyclobutyl(((3aR,4R,6R,6aS)-6-(4-((2,4-dimethoxybenzyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)amino)cyclobutyl)propanoate 

Relevant academic research and scientific papers

Phosphoramidate protides of carbocyclic 2′,3′-dideoxy-2′, 3′-didehydro-7-deazaadenosine with potent activity against HIV and HBV

Synthesis of phosphoramidate protides of carbocyclic D- and L-2′,3′-dideoxy-2′,3′-didehydro-7-deazaadenosine by treatment of the nucleoside with phosphorochloridates in the presence of pyridine and t-BuMgCl is described. Several of these protides showed s

An improved synthesis of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine

[Figure not available: see fulltext.] An improved seven-step synthesis of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine from dimethyl malonate with 31% overall yield is described. The procedure is operationally simple and practical for the synthesis of the 4-chloro-7H-pyrrolo[2,3-d]pyrimidine building block.

Synthesis of some pyrrolo[2,3-d]pyrimidine and 1,2,3-triazole isonucleosides

Nucleoside analogues 8, 9, 10 and 11, in which a pyrrolo[2,3-d]pyrimidine ring is linked to a 2-hydroxymethyl-3-hydtoxytetrahydrofuran have been prepared The azide 16 used as an intermediate in the mutes to these compounds also gave access to the 1,2,3-triazole isonucleosides 12 and 13.

HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF

Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurologica

4-chloro-7H-pyrrolo[2,3-d]pyrimidine synthetic method

The invention discloses a 4-chloro-7H-pyrrolo[2,3-d]pyrimidine synthetic method. A compound is an important intermediate for synthesizing ruxolitinib and tofacitinib as a JAK inhibitor for treating rheumatoid arthritis. The 4-chloro-7H-pyrrolo[2,3-d]pyrimidine synthetic method comprises the following steps of by taking a compound I (4,6-dichloro-5-allyl pyrimidine) as a starting material, performing oxidation reaction on the compound I and ozone to produce a compound II; then performing nucleophilic substitution reaction on the compound II and triethyl orthoformate to produce a compound III; then performing nucleophilic substitution reaction on the compound III and ammonia gas to produce a compound IV; and finally, performing ring closing on the compound IV self in an acid environment to produce a compound V, i.e., 4-chloro-7H-pyrrolo[2,3-d]pyrimidine, wherein a synthetic route is shown as the following formula (described in the description). The synthetic method disclosed by the invention is cheap and available in raw materials, simple and short in synthetic route, low in cost, high in yield and easy in industrial production.

INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6

Disclosed are chemical entities that inhibit Uba6, each of which is a compound of Formula /: Formula (I) or a pharmaceutically acceptable salt thereof, wherein R*1 is -H or -CH3; and Y is Formula (II) or Formula (III), wherein R

PYRROLO[2,3-D]PYRIMIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS

The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.

CYCLOLIC HYDRAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS

Compounds of Formula I are provided, including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: wherein Z is selected from the group consisting of: which are useful as HIV attachment inhibitors.

FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Fused Bicyclic Pyrimidine Derivatives, compositions comprising a Fused Bicyclic Pyrimidine Derivative, and methods of using the Fused Bicyclic Pyrimidine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR) in a patient.

BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS

The present invention relates to Bicyclic Heterocycle Derivatives of Formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metaboli